Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.340NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.340NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.340NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.437NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.437NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.437NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.452NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.452NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.452NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.400NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.400NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.400NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.1.25NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.25NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.1.25NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.2.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.2.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.2.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.16 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.16 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.16 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.46.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.46.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.46.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.37 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.37 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-16669.2Singapore
AY.37 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.336NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.336NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.336NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.1.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.1.9NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.1.9NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.317NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.317NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.317NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.397NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.397NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CM.6.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CM.6.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CM.6.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.54NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.54NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.54NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
DR.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DR.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DR.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BF.7.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.7.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.27NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used